Navigation Links
Nycomed's Daxas(R) Shows Encouraging Preliminary Results in Phase III COPD Studies
Date:10/28/2008

- Both 12-month pivotal studies in patients with symptomatic Chronic Obstructive Pulmonary Disease (COPD) meet primary endpoints

- Data show reductions in moderate and severe exacerbations requiring medical intervention

- Application for marketing authorisation in EU and US expected in 2009

- Partnering process for commercialisation in the US to be initiated

ZURICH, Switzerland, Oct. 28 /PRNewswire/ -- Nycomed today announced encouraging results from a preliminary analysis of four Phase III trials of Daxas(R) (roflumilast) in the treatment of symptomatic COPD. Two pivotal 12-month studies met their primary endpoints, showing effects on exacerbation rates and pulmonary function (FEV1). Furthermore, two supporting six-month studies confirmed the efficacy of Daxas when used with standard bronchodilator treatments. Further analysis including the secondary endpoints is ongoing and full data from all four studies are expected to be published during 2009. In light of the initial data analysis, Nycomed expects to file for European and US marketing authorisation next year. The company will also initiate the process of identifying a partner to commercialise Daxas in the United States.

Commenting on today's announcement, Hakan Bjorklund, Chief Executive Officer of Nycomed, said: "We are extremely encouraged by the positive results from our preliminary analysis of four phase III trials involving more than 4,500 patients. We believe Daxas has the potential to make a significant contribution to COPD management and will therefore be a great addition to Nycomed's product portfolio."

Anders Ullman, Executive Vice President R&D, added: "COPD has a very high morbidity and mortality. Epidemiological data suggest that it is growing at a significant rate all around the world. Daxas is well placed to be the only anti-inflammatory product that specifically targets the inflammatory processes, which appear to play an important role in COPD. Wi
'/>"/>

SOURCE Nycomed
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Jellyfish Protein Shows Potential to Help With Memory
2. Research Shows How AHCC(R) May Help Fight Flu and Other Infectious Agents
3. New carbon material shows promise of storing large quantities of renewable electrical energy
4. Oil palm plantations are no substitute for tropical rainforests, a new study shows
5. Global Study Shows That Majority of Women with Osteoporosis Do Not Consider Themselves at Higher Risk for Fractures
6. Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School
7. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
8. Asthma Uncontrolled in More Than 40 Percent of Adults With the Disease, New Landmark Survey Shows
9. Atrium shows a strong financial performance for its first quarter
10. A Smoking Gene: deCODE Shows How a Single Variant in the Sequence of the Genome Confers Nicotine Dependence and Risk of Lung Cancer and Other Disease
11. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... zFlo Motion , a US leader in biomechanics software ... a new partner. STT-Systems has developed an impressive ... with offerings in the optical-motion capture, 3D scanning, and industrial ... unit), iSen, is opening eyes around the world. With no ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Selexis SA, ... mammalian Research Cell Banks (RCBs) used for drug discovery ... Cell Banks will include Next-Generation Sequencing (NGS) ... architecture de-risks biologic manufacturing by ensuring the integrity of ...
(Date:1/22/2015)... , Jan. 22, 2015   Cypher Genomics, Inc., ... Inc. (NASDAQ: SQNM ), the leading ... for next generation noninvasive prenatal tests (NIPT). Through ... technology, called Mantis™, to advance analysis of clinically-relevant ...
(Date:1/22/2015)... , Jan. 22, 2015  Derma Sciences, Inc. ... company focused on advanced wound care, announces that ... tissues, have been added to the Premier, Inc. ... the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® product ...
Breaking Biology Technology:3D Motion Capture Just Got Easy 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... Biotech Inc. (TSX: ONC, NASDAQ: ONCY ) ... U.K. trial of REOLYSIN(R) combined with paclitaxel/carboplatin for patients ... Meeting on Replicating Oncolytic Virus Therapeutics. The meeting is ... 22nd, 2009. The principal investigator for the trial is ...
... Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to ... with Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) to ... Lifeline Biotechnologies for a combination of stock, assumption ... originally purchased the products from Lifeline Biotechnologies in ...
... Inc. (OTC Bulletin Board: OXBO) today announced the expansion of ... Melville Engle to the board.Engle has over 27 years experience ... money on Wall Street, launched hundreds of products, and has ... Dey LP, where he was the firm,s president and CEO. ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial 3Solos Endoscopy, Inc. Sells Ovascope and Mastascope Product Line to Lifeline Biotechnologies, Inc. 2Oxygen Biotherapeutics, Inc. Expands Board of Directors 2
(Date:12/15/2014)... 12, 2014 Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ... Facial Recognition Market 2015-2019" report to their offering. ... Facial recognition is a technology used for the identification ... feature of a person such as nose, jaw edges, ...
(Date:12/11/2014)... N.C. , Dec. 10, 2014  That blood pressure plays ... a while. Hypertension – the medical term for high blood ... early 1800s, and the inflatable cuff that,s used in measuring ... however, mean there,s nothing new about hypertension, its triggers and ...
(Date:12/10/2014)... 9, 2014  Valencell, a leader in performance biometric data ... demand from its licensees for highly accurate, clinically validated ... solely coming from fitness and health sectors, but first ... wearable is only as useful as the biometric data ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... known already for its role in schizophrenia has ... to a report in todays advance on-line issue of ... Medical Center (BIDMC), the study further suggests that a ... marker and therapeutic supplement for the treatment of this ...
... allows straightforward migration to EAC ePassport technology, ... Entrust, Inc. (Nasdaq: ENTU ) will provide ... to help authenticate sensitive,biometric information stored on machine ... -- which will be available to nearly 23 ...
... the University of Amsterdam have discovered how to keep ... the molecular level. The story of how the ... combating other plant diseases, is published May 9th in ... agriculturalists are continuously battling the ability of plant pathogens ...
Cached Biology News:A new gene trigger for pregnancy disorder identified 2Entrust, Hewlett Packard Partner to Deploy Taiwanese ePassports, Authenticate Biometric Data 2Entrust, Hewlett Packard Partner to Deploy Taiwanese ePassports, Authenticate Biometric Data 3
...
Normal Hamster Serum...
... Short Stroke Thrust Slide is designed for ... envelopes are limited and substantial side-loading is ... bumpers provide millions of trouble-free cycles even ... composite bushings or recirculating ball bearings , ...
Alkaline Phosphatase (E. coli C75), 100 units. Removes 5'-phosphates from DNA. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Alkaline Phosphatases....
Biology Products: